Previous analyses from a randomized trial in women aged 24-45 have shown the quadrivalent HPV vaccine to be efficacious in the prevention of infection , cervical intraepithelial neoplasia ( CIN ) and external genital lesions ( EGL ) related to HPV 6/11/16 / 18 through 4 years .